Identifying therapeutic vulnerabilities in lung cancer: application of a chemistry-first approach

Sharon R. Pine, Bríd M. Ryan


In the last three decades, 5-year relative survival rates for lung cancer improved slightly, from 14.3%, 15.5%, and 18.4% (1). One of the reasons for these dismal survival rates is that most patients present with advanced-stage disease, a time during which systemic therapies are unlikely to be curative.